SCHEMBL6834518

SCHEMBL6834518

Fc1ccc2c(c1)-c1[nH]c(-c3ccccn3)nc1CCC2

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 6/20 0.68
CBFB Q13951 9/20 0.53
METAP2 P50579 7/20 0.53
METAP1 P53582 6/20 0.53
NPC1 O15118 3/20 0.41
LMNA P02545 3/20 0.41
PKM P14618 3/20 0.41
RAB9A P51151 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 1/20 0.41
HPGD P15428 2/20 0.41
MTOR P42345 1/20 0.41
IDO1 P14902 1/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835219 0.86 NPY5R (0.68) NPY5RCBFBMETAP2METAP1NPC1
SCHEMBL6837109 0.85 NPY5R (0.64) NPY5RCBFBMETAP2METAP1NPC1
SCHEMBL6834673 0.81 NPY5R (0.67) NPY5RLMNAKDM4EMAPTHPGD
SCHEMBL6836929 0.79 NPY5R (0.69) NPY5RNPC1RAB9ASMN1; SMN2KDM4E
SCHEMBL6837099 0.74 NPY5R (0.53) NPY5RCBFBMETAP2METAP1
SCHEMBL5945579 0.71 NPY5R (0.46) NPY5RCBFBMETAP2METAP1NPC1
SCHEMBL30692552 0.70 CBFB (0.78) CBFBMETAP2METAP1NPC1LMNA
SCHEMBL124265 0.70 CBFB (0.78) CBFBMETAP2METAP1NPC1LMNA
SCHEMBL6835211 0.69 NPY5R (0.66) NPY5RNPC1LMNARAB9ASMN1; SMN2
SCHEMBL6835188 0.67 NPY5R (0.61) NPY5RNPC1RAB9AKMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040198791-A1 Fused imidazole derivative FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198791-A1 Fused imidazole derivative H1-0, H1-5, H1-3 NPY5R 983/4885CBFB 2692/4885METAP2 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.